Costs and health impact of delayed implementation of a national hepatitis B treatment program in China
Authors:
Open Access
- 8 July 2022
- journal article
- research article
- Published by International Society of Global Health in Journal of Global Health
- Vol. 12, 04043
Abstract
In response to the United Nations’ 2030 Sustainable Development Goal to combat viral hepatitis, in 2016 the WHO issued the first global health sector strategy on viral hepatitis to eliminate viral hepatitis as a public health problem by 2030 [1]. Endorsed by all WHO member states, including China, the strategy set important prevention and vaccination […]Keywords
This publication has 40 references indexed in Scilit:
- Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis BGastroenterology, 2011
- Carriers of Inactive Hepatitis B Virus Are Still at Risk for Hepatocellular Carcinoma and Liver-Related DeathGastroenterology, 2010
- Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccinationVaccine, 2009
- Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #Hepatology, 2009
- Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factorsJournal of Hepatology, 2008
- Natural History of Hepatitis B Virus Infection: An Update for CliniciansMayo Clinic Proceedings, 2007
- HBsAg seroclearance in asymptomatic carriers of high endemic areasHepatology, 2007
- Chronic hepatitis B virus infection in the Asia–Pacific region and Africa: Review of disease progressionJournal of Gastroenterology and Hepatology, 2005
- Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearanceJournal of Hepatology, 2005
- Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis BHepatology, 2002